Zhishang Chemical

Welcome to Zhishang Chemical      +86-176 5311 3209     Simon@sdzschem.com

Zhishang Chemical
Close this search box.

Baloxavir Dose CAS 1985605-59-1

Molecular Formula: C24H19F2N3O4S

Formula Weight: 483.49

ZSpharmac: Baloxavir Dose Supplement

Product Name: Baloxavir Dose
CAS No: 1985605-59-1
Purity: 99%

Basic Info

Product Name:Baloxavir Dose
Other Names:Baloxavir
Place of Origin:Shandong, China
Brand Name:ZSpharmac
Type:Pharmaceutical Raw Materials
Appearance:White Flakes
Storage:Ventilated And Dry
Provide:Baloxavir Dose MSDS;
Baloxavir Dose COA

What is Baloxavir Dose?

Baloxavirmarboxil is a third-generation anti-influenza chemical drug. The original company is Shionogi Pharmaceutical of Japan, and it is developed globally by Roche and it; The first new anti-influenza drug with an innovative mechanism of action approved by the US FDA is a first-in-class, single-dose oral drug with a new anti-influenza mechanism of action, designed to combat influenza A and B viruses, including Tamiflu Tasvir) resistant influenza strains and avian influenza strains (H7N9, H5N1). Studies have shown that the new drug can be effective in a single oral dose when used to treat acute influenza patients over 12 years old and whose flu symptoms last less than 48 hours.

Baloxavir Dose Properties:

Boiling point 644.7±65.0 °C(Predicted)
density 1.63±0.1 g/cm3(Predicted)
CAS DataBase Reference1985605-59-1


Baloxavir Dose Uses

  1. Baloxavir Dose is a flu medicine, an antiviral medicine, for individuals 12 years of age or older who have had symptoms of this infection within 48 hours. The efficacy of Baloxavir Dose administered after 48 hours has not been tested.
  2. Baloxavir Dose treats acute uncomplicated influenza in people 12 years of age and older who are at risk for complications from influenza.
  3. Baloxavir Dose for post-exposure prophylaxis against influenza (flu) in people 12 years of age and older following contact with someone with the flu.

Baloxavir Dose Mechanism of Action

Baloxavir (trade name Xofluza) works by inhibiting the cap-dependent endonuclease in influenza virus, the mechanism by which the genetic material of influenza virus is carried in RNA, its cap-dependent endonuclease Its main role is to help genome replication, that is, to help influenza virus replicate progeny. As an inhibitor of cap-dependent endonuclease, efoloza inhibits the enzymatic reaction and makes the viral genome unable to replicate, thereby blocking the proliferation of the virus as soon as the virus enters the cell. Through this biological mechanism, Efoloza moves the prevention and control threshold forward, “smothering the virus in the cradle”, so it can quickly cure the flu.

Baloxavir Dose indications

In October 2019, Genentech, a subsidiary of Roche, announced that the FDA approved the expanded indication application for its new anti-influenza drug Xofluza (baloxavirmarboxil). Xofluza will be used to treat people 12 years of age and older at high risk for complications from the flu. These acute influenza patients have been infected for less than 48 hours without complications. Baloxavir is a “first-in-class” single-dose oral drug. It works against oseltamivir-resistant strains and avian influenza strains (H7N9, H5N1). The approval of this expanded indication is based on positive results from the Phase III CAPSTONE-2 trial. The CAPSTONE-2 trial was designed to evaluate the efficacy and safety of Xofluza compared with oseltamivir or placebo in patients over 12 years of age at high risk for influenza complications. Trial results showed that Xofluza significantly delayed the median time to onset of flu symptoms (102 hours vs 73 hours) in patients at high risk for flu complications. Other key findings included: Xofluza had similar efficacy (54 hours vs. 54 hours) compared to oseltamivir on the duration of flu symptoms; for type B virus, Xofluza was effective in a shorter period of time compared to placebo. Improved flu symptoms over time (75 hours vs 101 hours). In addition, Xofluza demonstrated good tolerability and safety.

Baloxavir Dose Synthetic Route Map


Baloxavir Dose Approved

BXM was developed for the market by Japanese pharmaceutical company Shionogi Co. and Switzerland-based Roche AG. The names of BXM and BXA appearing in the Shionogi research report are S-033188 and S-033447, respectively.
The Japanese Ministry of Health, Labour and Welfare (JMHLW) and the U.S. Food and Drug Administration (FDA) approved baloxavir marboxil based on evidence of benefit and side effects from two clinical trials in adults and children with uncomplicated influenza (Trial 1, 1518T0821 and Trial 2, NCT02954354), involved 1119 patients. Both trials included clinical sites and patients in Japan, with Trial 2 adding a clinical site in the United States.
As of September 2018, in the only report from a phase III randomized controlled trial, baloxavir reduced the duration of flu symptoms in otherwise healthy outpatients by approximately 1 day compared with placebo treatment, and was associated with Results of seltamivir treatment were quite group. On the first day after initiation of baloxavir, patients in the treatment group had a greater reduction in viral load than those in the oseltamivir or placebo groups; however, after five days, the effect of a single dose of baloxavir on viral load There was no difference from the effect observed after the full 5-day oseltamivir regimen in its treatment group.
Baloxavir marboxil was approved for sale in Japan in February 2018. In October 2018, the FDA approved it for the treatment of acute uncomplicated influenza for more than 48 hours in asymptomatic people 12 years and older. The FDA application for baloxavir marboxil was granted priority review in the United States, and Xofluza was approved by Shionogi & Co., Ltd. in October 2018. Specifically, the FDA approved baloxavir marboxil for people at high risk of developing flu-related complications. In October 2019, the FDA approved an updated indication for the treatment of acute uncomplicated influenza in people 12 years of age and older who are at risk for complications from influenza. In November 2020, the FDA approved an updated indication that includes influenza post-exposure prophylaxis for people 12 years of age and older following contact with someone with the flu.
Baloxavir marboxil was approved for medical use in Australia in February 2020.
Baloxavir marboxil is a single-dose oral antiviral drug whose safety and efficacy have been demonstrated in two randomized controlled clinical trials involving 1,832 subjects assigned to 48 Experience flu symptoms within hours of receiving baloxavir marboxil, placebo, or another antiviral flu treatment. In both trials, subjects who received baloxavir marboxil experienced shorter periods of symptom relief than subjects who received a placebo. In the second trial, subjects who received baloxavir marboxil and those who received other influenza treatments did not differ in the time to symptom relief.
The safety and efficacy of baloxavir marboxil in preventing post-influenza exposure is supported by a randomized, double-blind, controlled trial of 607 subjects aged 12 years and older who had home exposure to influenza patients received a single dose of baloxavir marboxil or a single dose of placebo. Of the 607 subjects, 303 received baloxavir marboxil and 304 received a placebo. The primary endpoint of the trial was the proportion of subjects who were infected with influenza virus and developed fever and at least one respiratory symptom from day 1 to day 10. 1% of subjects who received baloxavir marboxil met these criteria, compared with 13% of subjects who received placebo in clinical trials.
Baloxavir marboxil was approved for medical use in the European Union in January 2021.

Company Profile

ZhiShang Chemical is owned by ZhiShang Group is a professional new-type chemicals enterprise combined into research and development, production and sales .

The company’s competitive product is pharmaceutical raw materials and intermediates (especially carbohydrate derivatives Series), In recent years, the company has made a major breakthrough in food and feed additives, plant extraction, industrial chemicals industry .

The company insists on the spirit of “sincere management, strict quality control, customer as god” , get consistent high praise from customers at home and abroad.

Company Culture

Help China Chemicals to benefit the happiness of human life


Become the most trusted chemical supplier in the world


Striver – oriented, enrich employees, customer first, deep service, seek development


Be prepared for danger in times of peace, forge ahead actively, unity and cooperation, and be brave to fight

About Us

The production base is located in Zhangqiu chemical industry park and Tai’an high-tech chemical industry park. laboratory and workshop in strict accordance with the GMP standard and the product fit national ISO9001 and ISO2000 standards.

“Zhishang” products are exported to Europe, North and South America, the Middle East, Asia Pacific and Africa area, so as to establish a long-term and stable cooperation relationship with customer in the world.

Company Info
  • Business Type: Manufacturer
  • Product Range: Additive , Chemical Auxiliary & Catalyst , Organic Chemicals
  • Products/Service: Organic Intermediate,Inorganic Chemistry, APIs, Dyestuffs And Pigments, Fragrance And Spices, Food Additives
  • Total Employees: 51~100
  • Capital (Million US $): 10000000RMB
  • Year Established: 2016
Production Capacity
  • No. of Production Lines : 8
  • No. of QC Staff : 5 -10 People
  • OEM Services Provided : yes
  • Factory Size (Sq.meters) : 3,000-5,000 square meters
  • Certificate: ISO9001 , CE , GMP , API , MSDS
  • Factory Location : Diao Town Industry Park, Zhangqiu City, Jinan City, Shandong Province, China.


Pre-Sales Service

* Prompt reply and 24 hours online, professional team to provide best price and high quality product.

* Sample testing support.

* Every batch of products will be tested to ensureits quality.

*The packing also can be according the customers` requirment.

*Any inquiries will be replied within 24 hours.

*we provide Commerical Invoice, Packing List, Bill of loading, COA , Health certificate and Origin certificate. If your markets have any special requirements, let us know.


After-Sales Service

*The fact of logistics information monitoring.

* Any questions about the product can be consulted at any time.

*Product has any problem can return.


Do you accept sample order?

We will make samples before mass production, and after sample approved, we’ll begin mass production. Doing 100% inspection during production, then do random inspection before packing.



You can get free samples for some products,you only need to pay the shipping cost or arrange a courier to us and take the samples. You can send us your product specifications and requests,we will manufacture the products according to your requests.

What’s your MOQ?

Our MOQ is 1kg. But usually we accept less quantity such as 100g on the condition that sample charge is 100% paid.

Do you supply product report?

Yes. We’ll give you product analysis report before shipping.

  Is there a discount?

Different quantity has different discount.


1. ≤50kg, Express delivery recommended, usually called as DDU service;

2. ≤500kg, Air shipping recommended, usually called as FOB, CFR, or CIF service;

3. >500kg, sea shipping recommended, usually called as FOB, CFR, or CIF service;

4. For high value products, please select air shipping and express delivery for safe.

Get Amrinone Quotation